Science News for
QCOR 2016 Scientific Sessions

Quality of Care and Outcomes Research

Feb. 28 – March 1, 2016
Hyatt Regency | Phoenix, AZ

Welcome to #QCOR16

Mark Creager, MD, president of the American Heart Association, and Mikhail Kosiborod, chair of the program committee, welcome viewers to QCOR 2016 and provide an overview of some of the highlights that will take place during the meeting.

See all QCOR16 Abstracts

Virtual Attendance - Get CME/CE Credit

Learn more about conference virtual attendance and how it works.

Connect on Social Media

Use #QCOR16 to spread the news about the latest cardiovascular science.

Monday, February 29

Plenary.PS.02.Trials on Trial: What Can Be Done to Sustain and Preserve RCTs in the Future

Improving Randomized Control Trials

Mikhail Kosiborod, MD, QCOR 2016 program committee chair, and Adrian Hernandez, MD, vice-chair review the science presented in plenary session 1, "Trials on Trial: What Can Be Done to Sustain and Preserve RCTs in the Future?"

KISS Principle for Trials - Keep It Large and Simple
Robert Harrington | Stanford University, Stanford, CA

The Consumer Reports Guide to Trials
Sanjay Kaul | Cedars-Sinai Medical Center, Los Angeles, CA

AOS.01-Abstract Oral Session: QCOR 2016 Young Investigator Award Candidates

QCOR 2016 Young Investigator Award Winner Jason Wasfy

Suzanne Arnold, MD, chair of the Young Clinicians and Investigators Committee for QCOR 2016, interviews the 2016 Young Investigator Award Winner Jason Wasfy, MD about his study, "Impact of Financial Penalties in Medicare's Hospital Readmissions Reductions Program."

WINNER Impact of Financial Penalties in Medicare's Hospital Readmissions Reductions Program

Jason H Wasfy | Massachusetts General Hospital, Boston, MA
Effect of Under-recognition on Angina Treatment in Stable Ischemic Heart Disease in Cardiology Outpatients: Seeing Eye to Eye is Key
Mohammed Qintar | Saint Lukes Mid America Heart Institute, Kansas City, MO
Comparative Effectiveness and Safety of Anticoagulant Therapy With Warfarin, Dabigatran, Apixaban, or Rivaroxaban in Patients With Nonvalvular Atrial Fibrillation
Gboyega Adeboyeje | HealthCore, Inc., Wilmington, DE
Patient Satisfaction and Healthcare Service Utilization Following Premature Acute Coronary Syndrome
Marisa Okano | McGill University, Montreal, QC, Canada
Trends in Hospitalization Rates and Mortality for Acute Myocardial Infarction by Community Income Level: 1999-2013
Erica S Spatz, Yale School of Medicine, New Haven, CT

Plenary.03 Your Money or Your Life: Are High-Cost Drugs Worth the Price?

Are High-Cost Drugs Worth the Price?

Karen Joynt, MD and David Cohen, MD provide a brief recap of plenary session III, "Your Money or Your Life: Are High-Cost Drugs Worth the Price?" which they moderated during QCOR 2016.

Tuesday, March 1

PS.04-The Quantitated Self

The Quanititated Self

Adrian Hernandez, MD and John Spertus, MD provide a recap of some of the science that was presented for Plenary Session IV, "The Quantitated Self," which they moderated Tuesday morning.

Quantitating Health from the Silicon Valley
Mintu Turakhia | Stanford University, Palo Alto, CA

A New World of Engagement: The Health e Heart Initiative
Mark J Pletcher, | University of California, San Francisco, San Francisco, CA

AOS.04-Abstract Oral Session

Dying With a Left Ventricular Assist Device as Destination Therapy
Shannon M Dunlay | Mayo Clinic Rochester, Rochester, MN

Impact of CHA2DS2-VASc Risk Factors on Anticoagulant Prescription in Patients with Atrial Fibrillation: Insights From the NCDR® PINNACLE Registry
Lauren E Thompson | University of Colorado, Denver, CO